Michael Koby

Michael Koby co-founded 1315 Capital in 2014, after spending his entire career as a healthcare investor and operator, including experience with more than 25 growth equity investments. Prior to founding 1315 Capital, Michael was a Managing Director at Palm Ventures, a private-equity focused family office where he led all healthcare investing. While at Palm, Michael led investments in Enigma Diagnostics, Axcentria Pharmaceuticals, and JDS Therapeutics. He currently serves on the boards of CHC Solutions, Integration Health, JDS Therapeutics, Mosaic Diagnostics, Nu-Tek Biosciences, Nutrisense, and Triple Ring Technologies, and is a board observer for Biocoat.

Before Palm Ventures, Michael spent over a decade as an investor, including before and after business school, at Galen Partners, a healthcare growth equity investment firm. He also held business development roles at Novoste Corporation and Medtronic, Inc. Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co.

Michael received a BSc from Cornell University and an MBA in Healthcare Management from The Wharton School.